103 related articles for article (PubMed ID: 2548330)
1. Modification of foot-and-mouth disease virus after serial passages in the presence of antiviral polyclonal sera.
Carrillo EC; Rojas ER; Cavallaro L; Schiappacassi M; Campos R
Virology; 1989 Aug; 171(2):599-601. PubMed ID: 2548330
[TBL] [Abstract][Full Text] [Related]
2. Modification of foot-and-mouth disease virus O1 Caseros after serial passages in the presence of antiviral polyclonal sera.
Rojas ER; Carrillo E; Schiappacassi M; Campos R
J Virol; 1992 Jun; 66(6):3368-72. PubMed ID: 1374806
[TBL] [Abstract][Full Text] [Related]
3. Response of foot-and-mouth disease virus C3 Resende to immunological pressure exerted in vitro by antiviral polyclonal sera.
Schiappacassi M; Rieder Rojas E; Carrillo E; Campos R
Virus Res; 1995 Apr; 36(1):77-85. PubMed ID: 7542827
[TBL] [Abstract][Full Text] [Related]
4. Characterization of foot-and-mouth disease serotype asial viruses grown in the presence of polyclonal antisera in serology and nucleotide sequence analysis.
Kumar RM; Sanyal A; Hemadri D; Tosh C; Mohapatra JK; Bandyopadhyay SK
Arch Virol; 2004 Sep; 149(9):1801-14. PubMed ID: 15593421
[TBL] [Abstract][Full Text] [Related]
5. Distinct repertoire of antigenic variants of foot-and-mouth disease virus in the presence or absence of immune selection.
Borrego B; Novella IS; Giralt E; Andreu D; Domingo E
J Virol; 1993 Oct; 67(10):6071-9. PubMed ID: 7690417
[TBL] [Abstract][Full Text] [Related]
6. Characteristic in vitro evolution pattern of foot and mouth disease virus A81/Castellanos/Arg/87.
Mbayed V; Schiappacassi M; Corominas A; Campos R
Virus Res; 1997 May; 48(2):157-63. PubMed ID: 9175254
[TBL] [Abstract][Full Text] [Related]
7. Host cell selection of antigenic variants of foot-and-mouth disease virus.
Bolwell C; Brown AL; Barnett PV; Campbell RO; Clarke BE; Parry NR; Ouldridge EJ; Brown F; Rowlands DJ
J Gen Virol; 1989 Jan; 70 ( Pt 1)():45-57. PubMed ID: 2471782
[TBL] [Abstract][Full Text] [Related]
8. Analysis of foot-and-mouth disease virus type O1 Brugge neutralization epitopes using monoclonal antibodies.
Stave JW; Card JL; Morgan DO
J Gen Virol; 1986 Oct; 67 ( Pt 10)():2083-92. PubMed ID: 2428926
[TBL] [Abstract][Full Text] [Related]
9. Analysis of foot-and-mouth disease virus-neutralizing idiotypes from immune bovine and swine with anti-murine idiotype antibody probes.
Garmendia AE; Borca MV; Morgan DO; Baxt B
J Immunol; 1989 Nov; 143(9):3015-9. PubMed ID: 2553817
[TBL] [Abstract][Full Text] [Related]
10. Sequence variation in the gene for the immunogenic capsid protein VP1 of foot-and-mouth disease virus type A.
Weddell GN; Yansura DG; Dowbenko DJ; Hoatlin ME; Grubman MJ; Moore DM; Kleid DG
Proc Natl Acad Sci U S A; 1985 May; 82(9):2618-22. PubMed ID: 2986125
[TBL] [Abstract][Full Text] [Related]
11. Selection of antigenic variants of foot-and-mouth disease virus in the absence of antibodies, as revealed by an in situ assay.
Diez J; Mateu MG; Domingo E
J Gen Virol; 1989 Dec; 70 ( Pt 12)():3281-9. PubMed ID: 2481712
[TBL] [Abstract][Full Text] [Related]
12. Antigenic stability of foot-and-mouth disease virus variants on serial passage in cell culture.
Gonzalez MJ; Saiz JC; Laor O; Moore DM
J Virol; 1991 Jul; 65(7):3949-53. PubMed ID: 1645803
[TBL] [Abstract][Full Text] [Related]
13. Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus.
Baxt B; Vakharia V; Moore DM; Franke AJ; Morgan DO
J Virol; 1989 May; 63(5):2143-51. PubMed ID: 2467993
[TBL] [Abstract][Full Text] [Related]
14. Neutralization sites of type O1 foot-and-mouth disease virus defined by monoclonal antibodies and neutralization-escape virus variants.
Stave JW; Card JL; Morgan DO; Vakharia VN
Virology; 1988 Jan; 162(1):21-9. PubMed ID: 2827379
[TBL] [Abstract][Full Text] [Related]
15. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate.
Mayr GA; Chinsangaram J; Grubman MJ
Virology; 1999 Oct; 263(2):496-506. PubMed ID: 10544121
[TBL] [Abstract][Full Text] [Related]
16. [Neutralization of foot-and-mouth disease virus O1 Campos by antibodies induced by a synthetic peptide].
Piccone M; Zuloaga G; Marcovecchio F; Arese A; Monesiglio JC; Palma EL
Rev Argent Microbiol; 1988; 20(2):69-75. PubMed ID: 2845477
[TBL] [Abstract][Full Text] [Related]
17. Antigenic site variation in foot-and-mouth disease virus serotype O grown under vaccinal serum antibodies in vitro.
Sarangi LN; Mohapatra JK; Subramaniam S; Sanyal A; Pattnaik B
Virus Res; 2013 Sep; 176(1-2):273-9. PubMed ID: 23850868
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies to an Indian strain of type A foot-and-mouth disease virus.
Tosh C; Venkataramanan R; Pattnaik B; Hemadri D; Sanyal A
Acta Virol; 1999 Aug; 43(4):219-25. PubMed ID: 10749367
[TBL] [Abstract][Full Text] [Related]
19. Establishment of cell lines persistently infected with foot-and-mouth disease virus.
de la Torre JC; Dávila M; Sobrino F; Ortín J; Domingo E
Virology; 1985 Aug; 145(1):24-35. PubMed ID: 2990100
[TBL] [Abstract][Full Text] [Related]
20. Generation of a subtype-specific neutralization epitope in foot-and-mouth disease virus of a different subtype.
Hernández J; Martínez MA; Rocha E; Domingo E; Mateu MG
J Gen Virol; 1992 Jan; 73 ( Pt 1)():213-6. PubMed ID: 1370534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
